ESTRADIOL AND PROGESTERONE
Clinical safety rating: avoid
CYP3A4 inducers can decrease efficacy Can cause thromboembolic disorders.
Estradiol binds to and activates estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and non-genomic signaling pathways. Progesterone binds to the progesterone receptor (PR), regulating endometrial differentiation and inhibiting estrogen-induced mitogenesis.
| Metabolism | Estradiol is primarily metabolized in the liver via hydroxylation by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2C9, CYP2C19) to estrone and estriol, followed by conjugation (glucuronidation and sulfation). Progesterone is extensively metabolized in the liver via reduction by 5α- and 5β-reductases, 3α- and 3β-hydroxysteroid dehydrogenases, and conjugation with glucuronic acid. Key enzymes include CYP3A4 and CYP2C19. |
| Excretion | Estradiol is primarily excreted as glucuronide and sulfate conjugates in urine (approximately 80%) and feces (approximately 20%). Progesterone is excreted mainly as pregnanediol glucuronide in urine (50-60%) and lesser amounts in feces. |
| Half-life | Estradiol: terminal half-life 13-16 hours; steady-state achieved after 2-3 days with transdermal administration. Progesterone: terminal half-life 16-18 hours; micronized oral form has a half-life of approximately 17 hours. |
| Protein binding | Estradiol: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin. Progesterone: 96-99% bound to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Estradiol: 1.2-1.6 L/kg (large distribution to target tissues). Progesterone: 0.7-1.2 L/kg (extensive distribution, especially to adipose tissue). |
| Bioavailability | Estradiol: oral <5% (extensive first-pass metabolism); transdermal 10-15% relative to oral; intramuscular 100% (absolute). Progesterone: oral micronized <10%; vaginal 20-25% (relative to IM); intramuscular 100%. |
| Onset of Action | Oral estradiol: 2-4 hours for plasma concentration peak, clinical effects (vasomotor symptom relief) within 2-4 weeks. Transdermal estradiol: steady-state reached in 24-48 hours. Intramuscular estradiol: within 24 hours. Oral progesterone: 1-4 hours for peak, clinical effect (endometrial transformation) within days. Vaginal progesterone: absorption within 2-6 hours, clinical effect within days. |
| Duration of Action | Estradiol: sustained levels for duration of dosing (e.g., transdermal patch 3-4 days; oral daily). Progesterone: oral daily; vaginal/IM preparations provide sustained levels for 1-2 days. |
Estradiol 1 mg orally once daily plus progesterone 200 mg orally once daily for 12-14 days per cycle (or continuous combined regimen: estradiol 0.5-1 mg orally once daily plus progesterone 100 mg orally once daily). For hormone replacement therapy: estradiol 0.5-2 mg orally once daily continuously; medroxyprogesterone acetate 2.5-5 mg orally once daily for 12-14 days per month (if progesterone used). Menopausal vasomotor symptoms: estradiol 0.5-1 mg orally once daily; if uterus intact, add progesterone 200 mg orally once daily for 12 days per month or 100 mg orally once daily continuously. Osteoporosis prevention: estradiol 0.5 mg orally once daily; progesterone as above. Topical: estradiol transdermal system 0.025-0.1 mg/day applied once weekly; progesterone vaginal gel 4% or 8% inserted once daily. Dose titrated to minimum effective. Maximum daily estradiol dose: 2 mg orally.
| Dosage form | CAPSULE |
| Renal impairment | For estradiol: no dosage adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Severe renal impairment (CrCl <30 mL/min): use with caution; consider dose reduction or alternative therapy due to limited data. For progesterone: no specific adjustment recommended; use with caution in renal impairment. Not studied in dialysis. |
| Liver impairment | Estradiol: contraindicated in severe hepatic dysfunction (Child-Pugh class C). Mild to moderate impairment (Child-Pugh class A or B): initiate at lowest dose and titrate cautiously; monitor hepatic enzymes. Progesterone: contraindicated in severe hepatic disease. For mild to moderate impairment: use with caution; reduce dose or frequency; monitor liver function. Avoid in active hepatitis or cholestatic jaundice. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CYP3A4 inducers can decrease efficacy Can cause thromboembolic disorders.
| FDA category | Positive |
| Breastfeeding | Estradiol and progesterone are excreted into breast milk in small amounts; M/P ratio for estradiol approximately 0.5-1.0, progesterone ~0.6. Use with caution as it may reduce milk production and composition; generally not recommended during breastfeeding unless benefits outweigh risks. |
| Teratogenic Risk | First trimester: Increased risk of congenital anomalies, including cardiac and limb defects, based on epidemiological studies; use contraindicated. Second trimester: Potential for masculinization of female fetuses with high-dose progesterone; avoid. Third trimester: No specific malformation risk but may cause adverse fetal effects (e.g., low birth weight) with prolonged use. |
■ FDA Black Box Warning
Estrogen-alone therapy increases the risk of endometrial cancer in women with an intact uterus. Estrogen plus progestin therapy increases the risk of breast cancer, venous thromboembolism, stroke, and dementia (in women ≥65 years). Use the lowest effective dose for the shortest duration consistent with treatment goals.
| Common Effects | abnormal uterine bleeding |
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer)","Active or history of venous thromboembolism (DVT, PE)","Active or history of arterial thromboembolism (e.g., stroke, MI)","Known thrombophilic disorders (e.g., protein C/S deficiency, antiphospholipid syndrome)","Active or history of liver disease or liver tumors (benign or malignant)","Known hypersensitivity to estradiol or progesterone","Pregnancy or suspected pregnancy","Lactation (unless clearly needed)"]
| Precautions | ["Risk of thromboembolic disorders (DVT, PE, stroke) – discontinue if occurs","Increased risk of endometrial cancer – add progestin in women with an intact uterus","Increased risk of breast cancer – use with caution in patients with strong family history","Cardiovascular events (MI, stroke) – increased risk in women with preexisting CV disease","Dementia – avoid use in women ≥65 years unless no alternatives","Gallbladder disease – may increase risk","Hepatic impairment – use caution; contraindicated in severe disease","Hypertriglyceridemia – monitor triglycerides","Fluid retention – monitor in conditions like asthma, migraine, renal dysfunction","Altered glucose tolerance – monitor if diabetic","Hypocalcemia – caution in hypoparathyroidism","Ocular effects – discontinue if sudden vision loss, proptosis, or diploid"] |
Loading safety data…
| Pediatric use |
| Not indicated for use in children for hormone replacement or contraception (estradiol/progesterone combinations may be used for delayed puberty or induction of puberty: estradiol 0.25-0.5 mg orally once daily initially, titrate slowly; progesterone may be added after breast development or withdrawal bleeding. Individualize based on Tanner stage and serum estradiol levels. No established weight-based dosing; pediatric use limited and requires specialist guidance. |
| Geriatric use | Start at low end of dosing range (estradiol 0.5 mg orally once daily or transdermal 0.025 mg/day). Use minimum effective dose for shortest duration. Consider non-hormonal alternatives for vasomotor symptoms if >65 years due to increased risk of thromboembolism, stroke, and dementia. Monitor for bone density and gynecologic malignancies. Progesterone: lower dose (100 mg orally once daily rather than 200 mg) if used cyclically. Avoid in patients >75 years without specific indication. |
| Fetal Monitoring | Monitor maternal blood pressure, liver function, and signs of thromboembolism. Fetal ultrasound for growth and anatomy if exposure occurs. Assess for signs of masculinization in female fetuses if high-dose progesterone used. |
| Fertility Effects | Can inhibit ovulation via negative feedback on gonadotropins; used in contraceptives. After discontinuation, fertility returns to baseline typically within 1-3 cycles. Chronic use may delay return to fertility. |